Two new projects for medical and diagnostic innovation funded through the SPARK Pisa call

RECAST and the gliflozin mechanism

RECAST is coordinated by Professor Sabrina Taliani of the Department of Pharmacy, in collaboration with Dr Luca Menichetti's group at the CNR Institute of Clinical Physiology in Pisa. Its stated objective is to develop a novel PET tracer capable of quantifying tissue distribution and clarifying how gliflozins act at the myocardial level. The choice of target is itself notable. Gliflozins, originally approved for type 2 diabetes, have shown reductions in morbidity and mortality even in non-diabetic heart failure cohorts, yet the underlying pharmacodynamic pathway in cardiac tissue remains incompletely characterized. A tracer that allows direct visualization of drug-tissue interaction would, in principle, give clinicians a mechanistic readout rather than a downstream surrogate. For the longevity audience, this matters because the class sits at the intersection of metabolic regulation, renal handling, and cardiac resilience, three axes consistently flagged in biomarker literature as modifiable drivers of all-cause mortality. The project also illustrates the kind of TRL 3–5 translational work that SPARK Pisa is structured to fund, bridging early-stage academic discovery and functional prototyping.

Vi3Dgo and digital dermatology

The second funded project, Vi3Dgo, is coordinated by Professor Paolo Neri of the Department of Civil and Industrial Engineering. The press materials describe it as a digital tool for monitoring dermatological conditions. We observe less mechanistic detail in the public communication, and the project description is more engineering-oriented than biomarker-oriented. From a longevity perspective, dermatological monitoring holds modest but non-trivial relevance: cutaneous changes can serve as early phenotypic markers of systemic processes, including glycemic dysregulation, inflammatory load, and vascular aging, though the strength of that signal depends heavily on the specific biomarker panel deployed. We will note the project for follow-up once peer-reviewed outputs emerge, rather than overstating its current clinical reach.

What to watch

SPARK Pisa operates as the Italian node of the SPARK Global network, founded at Stanford and now comprising more than 50 academic institutions. The programme explicitly funds projects at Technology Readiness Levels 3 to 5, meaning outputs are expected as proof-of-concept data, not validated clinical tools. The reasonable reading is that RECAST will, over the next funding cycle, produce preclinical imaging evidence of gliflozin myocardial engagement. That evidence, if replicated, could refine patient stratification in heart failure and clarify whether the cardioprotective efficacy of the class is consistent across myocardial phenotypes. For self-optimizing readers, the immediate takeaway is observational: gliflozins remain a well-evidenced intervention within their approved indications, and mechanistic imaging studies of this kind are precisely what the field needs to move beyond population-level effect sizes toward individualized targeting. We will track the resulting publications and patent filings as they surface.